---
figid: PMC7360684__fcell-08-00605-g002
figtitle: Canonical TGFB signaling pathway and TGFB signaling targeting therapies
organisms:
- Adenoviridae
- Rous sarcoma virus
- Avian sarcoma virus
- Moloney murine sarcoma virus
- Gallus gallus
- Danio rerio
- Xenopus laevis
- Homo sapiens
- Mus musculus
- Trypanosoma cruzi
organisms_ner:
- Homo sapiens
- Mus musculus
- Gallus gallus
- Danio rerio
- Xenopus laevis
pmcid: PMC7360684
filename: fcell-08-00605-g002.jpg
figlink: pmc/articles/PMC7360684/figure/F2/
number: F2
caption: Canonical TGF-β signaling pathway and TGF-β signaling targeting therapies.
  After TGF-β mRNA translation (step I) and secretion, the large latent complex (LLC)
  composed of TGF-β, latency associated peptide (LAP), and latent TGF-β binding protein
  (LTBP) is deposited to the extracellular matrix (ECM). The interaction between LTBP
  and integrins increases TGF-β:LAP dissociation and TGF-β activation (step II). TGF-β
  binding to surface receptors (step III) is followed by TβRII-mediated TβRI transphosphorylation
  (step IV). The signaling is then transduced to cytosol by TβRI-induced phosphorylation
  of SMAD2 and 3 (step V), followed by their association with SMAD4, accumulation
  in the nucleus and regulation of target genes transcription. Anti-TGF-β therapies
  target critical steps in order to impair TGF-β signaling. Antisense oligonucleotides
  (ASOs) prevent the translation of TGF-β mRNA (step I). Anti-integrins prevent TGF-β
  activation (step II). Ligand traps avoid cytokine binding to its receptors (step
  III). TβRII and TβRI kinase inhibitors block type II-mediated type I receptor phosphorylation
  (step IV) and type I-mediated SMAD2 and 3 phosphorylation (step V), respectively.
papertitle: 'On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer
  Treatments: What Are Remaining Challenges?.'
reftext: Adilson Fonseca Teixeira, et al. Front Cell Dev Biol. 2020;8:605.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9655632
figid_alias: PMC7360684__F2
figtype: Figure
redirect_from: /figures/PMC7360684__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7360684__fcell-08-00605-g002.html
  '@type': Dataset
  description: Canonical TGF-β signaling pathway and TGF-β signaling targeting therapies.
    After TGF-β mRNA translation (step I) and secretion, the large latent complex
    (LLC) composed of TGF-β, latency associated peptide (LAP), and latent TGF-β binding
    protein (LTBP) is deposited to the extracellular matrix (ECM). The interaction
    between LTBP and integrins increases TGF-β:LAP dissociation and TGF-β activation
    (step II). TGF-β binding to surface receptors (step III) is followed by TβRII-mediated
    TβRI transphosphorylation (step IV). The signaling is then transduced to cytosol
    by TβRI-induced phosphorylation of SMAD2 and 3 (step V), followed by their association
    with SMAD4, accumulation in the nucleus and regulation of target genes transcription.
    Anti-TGF-β therapies target critical steps in order to impair TGF-β signaling.
    Antisense oligonucleotides (ASOs) prevent the translation of TGF-β mRNA (step
    I). Anti-integrins prevent TGF-β activation (step II). Ligand traps avoid cytokine
    binding to its receptors (step III). TβRII and TβRI kinase inhibitors block type
    II-mediated type I receptor phosphorylation (step IV) and type I-mediated SMAD2
    and 3 phosphorylation (step V), respectively.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - TGFB1
  - TGFB2
  - TGFB3
  - TRAP
  - ACP5
  - CD40LG
  - TRAF2
  - TRRAP
  - TDRD7
  - SCYL1
  - TGFBR2
  - TGFBR1
  - SMAD2
  - SMAD3
  - SMAD6
  - SMAD7
  - SMAD4
  - MYC
  - SERPINE1
  - Tgfb1
  - Ltbp1
  - Acp5
  - Ssr4
  - Cd40
  - Cd40lg
  - Tgfbr2
  - Tgfbr1
  - Smad2
  - Smad3
  - Smad6
  - Smad7
  - Smad4
  - Myc
  - Nol3
  - Serpine1
  - Serpine2
  - SMAD10
  - acp5a
  - pak2a
  - itpka
  - smad2
  - smad3a
  - smad6a
  - smad7
  - smad4a
  - smad4b
  - myca
  - mycbp2
  - serpine1
  - tgfb1.L
  - tgfb1.S
  - eomes.L
  - eomes.S
  - smad2.L
  - smad2.S
  - smad3.L
  - smad3.S
  - smad6.L
  - smad7.L
  - smad4.L
  - smad4.S
  - myc.S
  - myc.L
---
